Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Affaires autochtones
• Budget
• Commerce intérieur
• Commerce international
• Développement régional
• Environnement
• Impôts et finances
• Industrie
• Marchés publics
• Propriété intellectuelle
• Questions touchant les consommateurs
• Recherche et développement
• Santé
• Sciences et technologies

Détails sur l'objet

Politique ou Programme

• Canadian Institutes of Health (CIHR) initiatives, such as the Drug Safety and Effectiveness Network (DSEN), and various research programs, particularly as they relate to public/private research and development partnerships
• Environment Canada and/or Food and Drugs Act regulations as they relate to the safe and environmentally responsible disposal of biopharmaceutical compounds.
• Existing or proposed policies and programs related to ensuring availability and access to effective cancer treatments for Canadian patients.
• Existing or proposed policies and programs related to improving access to effective treatments for common mental health and addiction disorders for Canadian patients.
• Federal Health Partnership with respect to the co-ordination of federal health benefit plan policies and programs.
• Federal policies related to, and interactions with, the Canadian Agency for Drugs and Technologies in Health (CADTH) particularly pertaining to its Common Drug Review (CDR), Health Technology Assessment (HTA), and the Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) units.
• Health Canada support for, or partnerships with, the Canadian Network for Mood and Anxiety Treatments (CANMAT)
• Health Canada's "Notice of Compliance with Conditions (NOC/c)" policy with regards to therapeutic products
• Health benefits programs of Citizenship and Immigration Canada, Correctional Services of Canada, Health Canada (NIHB), the Department of National Defence, the Royal Canadian Mounted Police, and Veterans Affairs Canada with respect to decisions and policies which impact the reimbursement of biopharmaceutical therapeutic products for plan beneficiaries.
• International Trade Canada's "Invest in Canada" policies and programs with respect to investment, business development and innovation in the life sciences industry sector.
• Mobilizing Science and Technology to Canada's Advantage, the federal science and technology strategy, with respect to the health and related life sciences and technologies priority area
• Modernization of Health Canada's Progressive Licensing framework as it relates to the review and approval of biopharmaceutical products
• National Pharmaceutical Strategy (NPS) as it relates to the federal government's involvement in the federal/provincial/territorial governments' access to medicines framework
• Scientific Research and Experimental Development (SR&ED) Tax Incentive Program as it relates to investment in biopharmaceutical and related health technology innovation.

Politique ou Programme, Proposition législative, Projet de loi ou résolution

• International Trade policy initiatives related to implementing / strengthening the Canada-Europe Trade Agreement (CETA), including recognition of patent term restoration within Canada's intellectual property protection regime

Politique ou Programme, Règlement

• Data exclusivity as it relates to the use of Natural Health Products in biopharmaceutical preparations.
• Patent Act as it relates to the regulation of intellectual property for therapeutic products

Proposition législative, Projet de loi ou résolution

• Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products

Proposition législative, Projet de loi ou résolution, Règlement

• Food and Drugs Act & regulations as they relate to export restrictions and cross border trade of biopharmaceuticals.

Règlement

• Food and Drug Regulations as it relates to data protection (Section C.08.004) and the regulation and protection of biopharmaceutical products
• Patent Act with respect to Patented Medecines (Notice of Compliance (NOC)) Regulations
• Patented Medicines Prices Review Board (PMPRB) Regulations as they relate to reporting requirements and pricing guidelines

Techniques de communication

• Communication écrite
• Communication orale
• Appel au grand public
• As part of Industry associations & delegations

Institutions gouvernementales

• Affaires autochtones et Développement du Nord Canada
• Affaires étrangères et Commerce international Canada (MAECIC)
• Agence canadienne de développement international (ACDI)
• Agence de la santé publique du Canada (ASPC)
• Agence des services frontaliers du Canada (ASFC)
• Agence du revenu du Canada (ARC)
• Anciens Combattants Canada (ACC)
• Bureau de la concurrence Canada (BUCO)
• Chambre des communes
• Citoyenneté et Immigration Canada
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Défense nationale (MDN)
• Développement économique Canada pour les régions du Québec
• Environnement Canada
• Finances Canada (FIN)
• Gendarmerie royale du Canada (GRC)
• Industrie Canada
• Instituts de recherche en santé du Canada (IRSC)
• Justice Canada (JC)
• Santé Canada (SC)
• Secrétariat de l'ALÉNA
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Sénat du Canada
• Service correctionnel du Canada (SCC)

Adresse :
1000, rue de la Gauchetiere ouest
Suite 500
Montreal, QC  H3B 4W5
Canada

Numéro de téléphone : 514-844-8515
Numéro de fax : 514-844-5495  

Renseignements sur la société mère